INDV — Indivior Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1625297 ·
Last close
$36.88
Market Cap
$4.35B
52W High
$42.81
52W Low
$22.56
ADV30
2,007,449
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 343,000,000 | 293,000,000 | 159,000,000 | 122,000,000 | 1,233,000,000 | 222,000,000 | 1,440,000,000 |
| Mar 2026 | 317,000,000 | 277,000,000 | 137,000,000 | 89,000,000 | 1,197,000,000 | 175,000,000 | 1,341,000,000 |
| Dec 2025 | 358,000,000 | 291,000,000 | 83,000,000 | 102,000,000 | 1,201,000,000 | 195,000,000 | 1,300,000,000 |
| Sep 2025 | 314,000,000 | 231,000,000 | 44,000,000 | 42,000,000 | 1,416,000,000 | 445,000,000 | 1,623,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-41,000,000
Investing CF
$-70,000,000
Financing CF
$-176,000,000
CapEx
$-71,000,000
Dividends Paid
—
Buybacks
$-302,000,000
EPS Diluted TTM
$2.79
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-334,000,000
Inventory
$151,000,000
Receivables
$287,000,000
ST Investments
$0
EBIT TTM
$420,000,000
Pretax Income TTM
$393,000,000
Interest Exp TTM
$27,000,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,331,000,064
EBITDA
$576,000,000
Free Cash Flow
$86,500,000
Enterprise Value
$4,357,291,008
Total Cash
$222,000,000
Total Debt
$509,000,000
Shares Out
118,031,934
Trailing EPS
$2.79
Book Value
$-1.76
ROE
—
ROA
26.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,239,000,000 | 265,000,000 | 210,000,000 | 1,201,000,000 | 1,300,000,000 | -99,000,000 | -27,000,000 |
| Dec 2024 | 1,188,000,000 | 234,000,000 | 7,000,000 | 1,316,000,000 | 1,653,000,000 | -337,000,000 | 36,000,000 |
| Dec 2023 | 1,093,000,000 | 247,000,000 | -126,000,000 | 1,760,000,000 | 1,952,000,000 | -192,000,000 | -300,000,000 |
| Dec 2022 | 901,000,000 | 215,000,000 | -44,000,000 | 1,769,000,000 | 1,718,000,000 | 51,000,000 | -4,000,000 |
TTM Snapshot
Revenues TTM
$299,000,000
NetIncome TTM
$-97,000,000
OpCashFlow TTM
$0
Assets (Latest)
$1,758,000,000
Forward EPS
$4.88
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | $4.32B | $39.79 | — |
| ABCL | AbCellera Biologics Inc. | $4.51B | $13.92 | — |
| TNGX | Tango Therapeutics, Inc. | $4.10B | $24.30 | — |
| GIFLF | Grifols SA | $4.70B | $11.13 | — |
| TLPPF | Telix Pharmaceuticals Ltd | $3.97B | $11.67 | — |
News headlines (Yahoo Finance, 1h cache)
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
2026-09-17 11:00 · Yahoo
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
2026-09-14 13:30 · Yahoo
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
2026-09-02 15:30 · Yahoo
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-08-31 13:35 · Yahoo
3 Reasons Why Growth Investors Shouldn't Overlook Indivior Pharmaceuticals Inc. (INDV)
2026-08-27 16:45 · Yahoo
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan
2026-08-22 02:11 · Yahoo
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
2026-08-21 16:40 · Yahoo
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
2026-08-21 14:48 · Yahoo
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
2026-08-04 16:18 · Yahoo
Indivior Q2 Earnings Call Highlights
2026-08-03 14:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.